Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension
ConclusionsPlasma prolargin levels differentiate PAH patients from controls and the other investigated dyspnoea groups including HF. Its potential in PAH differentiation may be enhanced by inclusion in a multi ‐marker panel. Larger studies are needed to evaluate its discriminative ability of PAH in relation to other dyspnoea aetiologies and its potential role in PAH risk stratification and pathobiology.
Source: ESC Heart Failure - Category: Cardiology Authors: Mattias Arvidsson,
Abdulla Ahmed,
Habib Bouzina,
G öran Rådegran Tags: Original Research Article Source Type: research
More News: Brain | Cardiac Catheterization | Cardiology | Heart | Heart Failure | Hypertension | Neurology | Pulmonary Hypertension | Stroke | Study